Why is the FDA refusing Moderna's application for a new mRNA flu vaccine?

Core Viewpoint - The U.S. Food and Drug Administration (FDA) has declined to review Moderna's application for a new flu vaccine utilizing mRNA technology, which was awarded a Nobel Prize [1] Group 1: Company Impact - Moderna's application for a flu vaccine based on mRNA technology has been rejected by the FDA, which may hinder the company's expansion into the flu vaccine market [1] - The refusal from the FDA could impact Moderna's stock performance and investor sentiment, as the company seeks to diversify its vaccine portfolio beyond COVID-19 [1] Group 2: Industry Implications - The decision by the FDA raises questions about the regulatory landscape for mRNA vaccines in the broader vaccine industry, potentially affecting other companies exploring similar technologies [1] - The rejection may slow down the adoption of mRNA technology in flu vaccines, which could have implications for public health strategies and vaccine development timelines [1]